natalizumab-sztn 300 MG per 15 ML Injection

RxCUI: 2725173
RxNorm name: natalizumab-sztn 300 MG per 15 ML Injection
Display name: natalizumab-sztn 300 MG per 15 ML Injection
Full name: natalizumab-sztn 300 MG per 15 ML Injection
Term type: SY
Status: DailyMed mapping
Updated: 2026-06-04 23:39:27

Purple Book Biologic Products#

BLA, Proprietary name, Proper name table
BLA	Proprietary name	Proper name	License type	Status	Latest source
761322	Tyruko	natalizumab-sztn	351(k) Biosimilar	Rx	2026-06-01

RxNav Current And Historical NDCs#

RxNav current and historical NDC rows page 1 of 1 · 0 matching rows.

No records found.

UNII Substances#

UNII substance links page 1 of 1 · 0 matching rows.

No records found.

openFDA label cross-check#

Cross-check layer: openFDA label JSON enriches search and identifies hydration gaps. The DailyMed Structured Product Label remains the canonical label presentation on FDA.report. Every label matching the complete exact-identifier union is deduplicated and paginated below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
Brand	Generic	Manufacturer	SPL set ID	Effective date	Available safety fields	Join
TYRUKO	NATALIZUMAB-SZTN	Sandoz Inc	ef653c36-dd4b-4e71-9d2d-40b8fea24b67	2025-10-31	Boxed warning, Warnings, Adverse reactions	Exact identifier rxcui: 2725173

DailyMed RxNorm Mappings#

Set ID, RxNorm string, TTY table
Set ID	RxNorm string	TTY	SPL version	Label	Effective
ef653c36-dd4b-4e71-9d2d-40b8fea24b67	natalizumab-sztn 300 MG per 15 ML Injection	SY	13	These highlights do not include all the information needed to use TYRUKO ® safely and effectively. See full prescribing information for TYRUKO . TYRUKO (natalizumab-sztn) injection, for intravenous use Initial U.S. Approval: 2023 TYRUKO (natalizumab-sztn) is biosimilar* to TYSABRI ® (natalizumab).	20251031
ef653c36-dd4b-4e71-9d2d-40b8fea24b67	15 ML natalizumab-sztn 20 MG/ML Injection	SCD	13	These highlights do not include all the information needed to use TYRUKO ® safely and effectively. See full prescribing information for TYRUKO . TYRUKO (natalizumab-sztn) injection, for intravenous use Initial U.S. Approval: 2023 TYRUKO (natalizumab-sztn) is biosimilar* to TYSABRI ® (natalizumab).	20251031
ef653c36-dd4b-4e71-9d2d-40b8fea24b67	natalizumab-sztn 300 MG in 15 ML Injection	PSN	13	These highlights do not include all the information needed to use TYRUKO ® safely and effectively. See full prescribing information for TYRUKO . TYRUKO (natalizumab-sztn) injection, for intravenous use Initial U.S. Approval: 2023 TYRUKO (natalizumab-sztn) is biosimilar* to TYSABRI ® (natalizumab).	20251031